Moreover, Pembrolizumab (1, 2 μM) elevated the expression of Bax and Caspase-3 and dampened the bcl-2 expression in tumor cells versus the X-ray radiation (1 Gy) group (P < 0.05, Figure 1(g,h)). Here, BCL2 is linked to neoplasm.